Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 29 |
| Active Pipeline (Recruiting Now) | 9 (4) |
| Completed vs Stopped Early | 6 / 13 (44.8%) |
| Median Closed Actual Enrollment | 23 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Boston Children's Hospital | Boston, MA | 22 |
| Emory Winship Cancer Institute | Atlanta, GA | 4 |
| Washington University and Siteman Cancer Center | Saint Louis, MO | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05600426 | A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) | Phase III | TERMINATED |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boston Children's Hospital across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Boston Children's Hospital Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.